Kha Dinh, MD
Critical Care Medicine · Houston, TXNPI 1811252075
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (30.0%), education and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Maquet Cardiopulmonary GmbH at 56.2% of the total. 2025 is the largest year on record at $7,997, more than ten times the $178 reported in 2019. Among critical care medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $256.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Maquet Cardiopulmonary GmbH$7K
- Intuitive Surgical$4K
- AstraZeneca$422
- Insmed, Inc.$274
- Merit Medical Systems Inc$193
- Abbott$157
- plus $884 from 15 others
What the payments were for
- Consulting fees$4,00030%
- Speaking & faculty fees$2,37518%
- Travel & lodging$2,11816%
- Food & beverage$1,82014%
- Education$3,00023%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Maquet Cardiopulmonary GmbH | 5 | $7,483 |
| Intuitive Surgical | 5 | $3,901 |
| AstraZeneca | 7 | $422 |
| Insmed, Inc. | 6 | $274 |
| Merit Medical Systems Inc | 2 | $193 |
| Abbott | 2 | $157 |
| Tempus AI, Inc | 1 | $148 |
| Livanova USA, Inc. | 1 | $124 |
| Astellas Pharma US Inc | 5 | $113 |
| Boston Scientific | 4 | $108 |
| ERBE USA Inc | 3 | $93 |
| Pinnacle Biologics, Inc | 1 | $72 |
| Grifols USA, LLC | 2 | $47 |
| Sanofi | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Bayer | 1 | $24 |
| Coaptech, Inc. | 1 | $23 |
| Gilead | 1 | $23 |
| AbbVie | 1 | $21 |
| Body Vision Medical Inc. | 1 | $18 |
| Olympus America Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HLS Set$7,419
- ION$3,000
- Da Vinci Surgical System$709
- Arikayce$172
- Tempus Pixel$148
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$126
- FASENRA$125
- Hemolung Cartridge Kit$124
- TEZSPIRE$118
- AIRSUPRA$114
- AERO Stent and Delivery System$109
How this compares
$13,313 in reported general payments places this provider in the 90th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bosentan | 13 | $71,257 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $31,895 |
| OzempicSemaglutide | 11 | $10,293 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,442 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $988 |
| Eplerenone | 11 | $227 |
| Azithromycin | 13 | $51 |
| Prednisone | 16 | $42 |
| Amlodipine Besylate | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Bosentan | $24 | $71,25713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Houston
- Edwin ParsleyHouston$283K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
- Sami HossriHouston$34K
- George WilliamsHouston$33K
- Nicholas VillalobosHouston$26K
- Ranjan UpadhyayHouston$25K
- Deepa GoturHouston$23K
- Hany Abd-El MalekHouston$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.